Avadel Pharmaceuticals - 股票

Avadel Pharmaceuticals 负债 2024

Avadel Pharmaceuticals 负债

76.96 百万 USD

股票代码

AVDL

ISIN

US05337M1045

WKN

A2DJR8

在2024年,Avadel Pharmaceuticals的负债总额为76.96 百万 USD,与上一年153.93 百万 USD负债相比,差异为-50%

Avadel Pharmaceuticals Aktienanalyse

Avadel Pharmaceuticals在做什么?

Avadel Pharmaceuticals PLC is an Irish pharmaceutical company that focuses on the development, manufacturing, and marketing of pharmaceutical products. The company was founded in 1999 under the name Flamel Technologies and was renamed Avadel Pharmaceuticals in 2019 to support its rebranding strategy and expand its activities in the global market. Avadel's business model is based on the discovery and development of therapies for rare diseases and sleep-related disorders, as well as the manufacturing and marketing of generic drugs and specialty products. The company is divided into three main segments: specialty pharmaceuticals, generic pharmaceuticals, and the Pediarix division. Avadel's specialty pharmaceuticals segment focuses on developing drugs for patients with rare diseases such as Prader-Willi syndrome or narcolepsy. An example of an innovative product in this segment is Rekarbri, an ORP medication for the treatment of narcolepsy. It is the first drug in the EU specifically tailored to the specific needs of narcolepsy patients and has improved patients' quality of life. The generic pharmaceuticals segment of Avadel offers high-quality and cost-effective medications that treat commonly prescribed and everyday conditions such as pain, infections, depression, and anxiety disorders. Most products in this segment are manufactured in the USA and are available in many countries worldwide. Avadel's Pediarix division specializes in the development and manufacturing of children's medicines. This includes products for the treatment of attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorders (ASD). An example of a product from this segment is Reagila, a medication for the treatment of ADHD in children that is known for its improved efficacy and lower risk of side effects. Avadel also has a geographically distributed business structure that allows it to market its products worldwide. The company has a strong presence in the USA and is represented in Europe, Asia, and Australia. It has an impressive research and development infrastructure, including manufacturing facilities and research facilities, that allow it to meet the needs of its customers. Overall, Avadel Pharmaceuticals is a leading pharmaceutical company that focuses on researching new and innovative therapies for patients with rare diseases and sleep-related disorders. The company has demonstrated its ability to bring effective products to the market while maintaining the highest standards in quality assurance and customer service. It is expected that Avadel will continue to grow in the future and introduce new and innovative products to help its customers and patients worldwide. Avadel Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

负债的详细信息

Avadel Pharmaceuticals的负债评估

Avadel Pharmaceuticals的负债包括公司对外界各方和投资者的财务承诺和债务。它们分为短期负债,即一年内到期的负债,和长期负债,即在较长时间段内到期的负债。对这些负债的详细评估对于评价Avadel Pharmaceuticals的财务稳定性、运营效率和长期可持续性至关重要。

年度对比

通过对Avadel Pharmaceuticals的负债进行年度对比,投资者可以识别公司财务定位的趋势、变化和异常。负债总额的减少通常表明财务状况的强化,而增加则可能表明投资、收购的增加或可能的财务压力。

对投资的影响

Avadel Pharmaceuticals的总负债在决定公司的杠杆作用和风险状况方面起到重要作用。投资者和分析师会仔细研究这个方面,以判断公司满足其财务承诺的能力,这将影响投资吸引力和信用评级。

负债波动的解读

Avadel Pharmaceuticals的负债结构变化反映了其财务管理和战略的变化。负债的减少反映了高效的财务管理或债务偿还,而增加则可能表明扩张、收购行动或运营成本的增加,这些都会对投资者产生不同的影响。

关于Avadel Pharmaceuticals股票的常见问题

Avadel Pharmaceuticals今年的负债有多高?

Avadel Pharmaceuticals今年的负债额为76.96 百万 USD。

Avadel Pharmaceuticals的负债与去年相比高了多少?

Avadel Pharmaceuticals的负债与去年相比,增加了-50% 下降了。

Avadel Pharmaceuticals的投资者面临高负债的后果是什么?

对于Avadel Pharmaceuticals的投资者来说,高额债务可能构成风险,因为它会使公司的财务状况变弱,可能会影响其履行责任的能力。

Avadel Pharmaceuticals的投资者面临低负债率会有什么后果?

低债务意味着Avadel Pharmaceuticals具有强大的财务地位,并且能够履行其义务,而不会过度负担其财务。

Avadel Pharmaceuticals的负债增加会对公司产生什么影响?

Avadel Pharmaceuticals的负债增加可能导致公司的义务增加,并可能更难以履行其财务责任。

Avadel Pharmaceuticals的负债减少会对公司产生什么影响?

Avadel Pharmaceuticals的负债减少可能意味着公司的负担较轻,并且拥有更强大的财务地位,这将使其更容易履行其财务义务。

是什么因素影响了Avadel Pharmaceuticals的负债?

一些可能影响Avadel Pharmaceuticals负债的因素包括投资、收购、运营成本和营业收入的发展。

Avadel Pharmaceuticals的负债总额为何对投资者如此重要?

Avadel Pharmaceuticals的负债对投资者来说很重要,因为它们是公司财务稳定性的指标,且能向投资者提供关于公司如何履行其财务义务的信息。

Avadel Pharmaceuticals可以采取哪些战略措施来改变负债?

为了改变负债状况,Avadel Pharmaceuticals可以采取的措施包括节约成本、提高销售额、出售资产、获得投资或建立合作伙伴关系等。企业进行全面的财务状况审查以选择最佳的战略措施是非常重要的。

Avadel Pharmaceuticals支付多少股息?

在过去的12个月中,Avadel Pharmaceuticals支付了 的股息。这相当于大约的股息收益率。在未来的12个月内,Avadel Pharmaceuticals预计将支付0 USD的股息。

Avadel Pharmaceuticals的股息收益率有多高?

Avadel Pharmaceuticals当前的股息收益率为。

Avadel Pharmaceuticals什么时候支付股息?

Avadel Pharmaceuticals按季度支付股息。这些股息将在月份分发。

Avadel Pharmaceuticals的股息有多安全?

Avadel Pharmaceuticals 在过去0年里每年都支付了股息。

Avadel Pharmaceuticals的股息有多高?

预计未来12个月的股息将达到0 USD。这相当于0 %的股息收益率。

Avadel Pharmaceuticals位于哪个行业?

Avadel Pharmaceuticals 被分配到“健康”板块。

Wann musste ich die Aktien von Avadel Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

要获得Avadel Pharmaceuticals在支付的0 USD的最后一笔股息,你必须在的除息日之前持有该股票于你的账户中。

Avadel Pharmaceuticals最后一次支付股息是什么时候?

上一次股息发放日期为。

Avadel Pharmaceuticals在2023年的股息是多少?

在2023年,Avadel Pharmaceuticals 分配了0 USD作为股息。

Avadel Pharmaceuticals 的股息是以哪种货币支付的?

Avadel Pharmaceuticals的股息将以USD的形式分配。

股票储蓄计划为投资者提供了一种吸引人的方法,可以长期累积财富。主要优势之一是所谓的成本平均效应:通过定期投入固定金额于股票或股票基金,当价格低时自动买入更多份额,价格高时买入较少,这可能随着时间带来更优惠的平均每份成本。此外,股票储蓄计划还允许小额投资者接触到高价股票,因为他们可以用很小的金额参与其中。定期投资也促进了一种纪律投资策略,并有助于避免情绪化的决策,如冲动买卖。除此之外,投资者还能从股票的潜在增值以及可以再投资的股息分红中获益,这增强了复利效应,从而增加了投资资本的增长。

Andere Kennzahlen von Avadel Pharmaceuticals

我们对Avadel Pharmaceuticals 营业额股票的股票分析包括重要的财务指标,如收入、利润、市盈率、市销率、息税折旧摊销前利润,以及有关股息的信息。此外,我们还研究了诸如股票、市值、债务、股东权益和Avadel Pharmaceuticals 营业额的负债等方面。如果您在寻找关于这些主题的更详细信息,我们在子页面上提供了详细的分析: